Vitiligo and Treatment
| Autor: | Antigona Gerqari, Mybera Ferizi, Nita Krasniqi, Sadije Halimi, Mergita Ferizi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Autoimmune disease
medicine.medical_specialty education.field_of_study integumentary system business.industry Population Vitiligo medicine.disease Dermatology Melanin Pimecrolimus medicine General Earth and Planetary Sciences Clobetasol propionate skin and connective tissue diseases Prospective cohort study education business General Environmental Science medicine.drug |
| Zdroj: | Clinical Medicine Research. 4:195 |
| ISSN: | 2326-9049 |
| DOI: | 10.11648/j.cmr.20150406.15 |
| Popis: | Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|